Contact Lenses Forum - Lens 101
SITE SPONSOR
contact lenses

Go Back   Contact Lenses Forum - Lens 101 > News Archives > News Archives - 2006 > May 2006
Register FAQ Members List Calendar Search Today's Posts Mark Forums Read

May 2006 Contact Lens related news articles for May 2006


Join Lens 101Welcome to the Contact Lenses Forum - Lens 101 forums.

You are currently viewing our boards as a guest which gives you limited access to view most discussions and access our other features. By joining our free community you will have access to post topics, communicate privately with other members (PM), respond to polls, upload content and access many other special features. Registration is fast, simple and absolutely free so please, join our community today!

Pegaptanib Sodium Leads Increase in Intraocular Pressure in Patients With Glaucoma

This is a discussion on Pegaptanib Sodium Leads Increase in Intraocular Pressure in Patients With Glaucoma within the May 2006 forums; May 1, 2006 -- Patients whose age-related macular degeneration (ARMD) is treated with pegaptanib sodium ...


 
 
LinkBack Thread Tools Display Modes
Site Sponsor
  #1 (permalink)  
Old 05-04-2006, 10:34 AM
Administrator
 
Join Date: Oct 2004
Posts: 5,098
Default Pegaptanib Sodium Leads Increase in Intraocular Pressure in Patients With Glaucoma

May 1, 2006 -- Patients whose age-related macular degeneration (ARMD) is treated with pegaptanib sodium (Macugen) may run the risk of significantly increased intraocular pressure (IOP) that could eventually spell trouble for their optic nerves.

In a presentation here April 30th at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, investigators discussed how the use of Macugen can lead to increases in IOP that could ultimately prove harmful to patients with pre-existing glaucoma.

Macugen is meant to be delivered via intravitreal injections of 0.09 mL every 6 weeks for a period not to exceed 2 years. While it is known that such injections will lead to some "spiking" of IOP, the degree or duration of spiking has never been measured.

Allison Toler, optometrist, East Florida Eye Institute, Stuart, Florida, and Ronald Frenkel, MD, ophthalmologist, Bascom Palmer Eye Institute, University of Miami, Miami, Florida, enrolled 8 patients with glaucoma who were being treated with Macugen.

Patients' IOP levels were measured 1 minute after the Macugen injection, and then every 5 to 10 minutes until IOP returned to baseline. Over a 7-month period, the patient received a total of 31 injections.

Mean pre-injection IOP was 12.9 mm Hg and mean postinjection IOP was 39.4 mm Hg. One patient's IOP spiked as high as 55 mm Hg, requiring immediate anterior chamber paracentesis.

All patients received at least one IOP-lowering medication prior to the injection, and though this was helpful it did not prevent the increase in IOP, according to the researchers.

In most cases, the IOP returned to baseline, or near baseline levels within 30 minutes of the injection. Mean IOP within the first 10 minutes of the injection was 31.8 mm Hg, within 11 to 20 minutes it was 23.6 mm Hg, and by the 30-minute mark it was 20.9 mm Hg. By the time the patients returned for their first follow-up examination, their IOP had returned to baseline levels.

The researchers reported that when Macugen was compared with Avastin (bevacizumab), another agent used to prevent macular degeneration, the spikes in IOP were similar, but the spike following Avastin dissipated faster.

They concluded that physicians treating patients with glaucoma must be cautious in maintaining IOP at safe levels, and although there was no suggestion in this study that having IOP levels remain elevated to this degree for a relatively short period of time might be harmful, it would be wise to keep the IOP low at all times.

This study involved only patients with pre-existing glaucoma and for those patients, any change in IOP should be viewed with concern, according to the researchers. While they would not say this should definitely preclude such patients from receiving Macugen in the treatment of macular degeneration, physicians should view each case individually, and they may want to exercise added caution in offering such injections to patients with glaucoma.
__________________
Any news articles or press releases can be submitted as word or text documents to news@Lens101.com.

Archives Administrator
news@Lens101.com
 

Bookmark This Site


Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)
 
Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Trackbacks are On
Pingbacks are On
Refbacks are On



All times are GMT -5. The time now is 08:51 PM.


Contact Lenses

/ Contact Lens Forums
Daily Disposable Contact Lenses 2
1-2 Week Disposable Contact Lenses
Monthly Disposable Contact Lenses
Color Contact Lenses 2 3 4 5 6 7
Gas Permeable Contact Lenses 2 3
Toric Contact Lenses 2 3
Bifocal Contact Lenses 2
Vial Contact Lenses
Other Contact Lenses 2 3, & Contact Lens Care 2 3 4 5 6 7 8 9 10 11

Powered by vBulletin® Version 3.8.1
Copyright ©2000 - 2014, Jelsoft Enterprises Ltd.
SEO by vBSEO 3.2.0 RC7 ©2008, Crawlability, Inc.
Copyright 2001 - 2010 eyeTopics.com, Inc. All rights reserved.

Any materials provided on this web site are for informational purposes only. Have your eyes examined regularly and always follow your eye care professional's instructions for the proper use and care of your contact lenses. IF YOU ARE HAVING ANY UNEXPLAINED EYE DISCOMFORT, WATERING, VISION CHANGE OR REDNESS, REMOVE YOUR LENSES IMMEDIATELY AND CONSULT YOUR EYE CARE PROFESSIONAL BEFORE WEARING YOUR CONTACT LENSES AGAIN.

Site operated by eyeTopics.com, Inc.